Reza Karkhaneh, Hooshang Faghihi, Hamid Riazi-Esfahani, Mojtaba Abrishami, Fatemeh Bazvand, Nazanin Ebrahimiadib, Mohammadkarim Johari, Mohammadreza Akhlaghi, Nasser Shoeibi, Mohammad Hossein Norouzzadeh, Mohammad Reza Ansari Astaneh, Hassan Khojasteh, Marjan Imani Fooladi, Alireza Khodabande, Fariba Ghassemi, Elias Khalili Pour, Mohammad Zarei, Ahmad Mirshahi, Farhad Fazel, Hossein Ashraf, Seyedeh Maryam Hosseini, Maryam Dourandeesh, Mostafa Feghhi, Yousef Alizadeh, Hassan Behboudi, Pejvak Azadi, Araz Sabzvari, Hamidreza Kafi, Khalil Ghasemi Falavarjani
OBJECTIVE: To assess the non-inferiority of biosimilar aflibercept (CinnaGen Company, Iran) (P041) to the originator aflibercept (Regeneron, US) (AFL) in terms of efficacy, safety, and immunogenicity. DESIGN: This was a phase Ш, 52-week, multicenter, randomized, double-masked, and active control trial involving eyes in a 1:1 ratio. SUBJECTS: Patients with active subfoveal choroidal neovascularization secondary to age-related macular degeneration randomized into the two groups of P041 and AFL...
February 28, 2024: Ophthalmology Retina